Revenue Update on Titan Pharmaceuticals(NASDAQ:TTNP)

Titan Pharmaceuticals(NASDAQ:TTNP) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $0.55.

Several Insider Transactions has been reported to the SEC. On Jul 19, 2016, Joseph A Akers (director) purchased 13,000 shares at $4.82 per share price.Also, On Jul 19, 2016, Sunil Bhonsle (CEO) purchased 10,000 shares at $4.95 per share price.On May 31, 2016, James R Mcnab (director) purchased 20,000 shares at $7.03 per share price, according to the Form-4 filing with the securities and exchange commission.

Titan Pharmaceuticals Inc. (Titan) is a specialty pharmaceutical company developing therapeutics for the treatment of medical disorders. The Company’s product development programs utilize its long-term drug delivery platform ProNeura. The Company’s drug candidate Probuphine is being developed for the long term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. Titan’s drug candidate Probuphine is in Phase III clinical study stage. The Company is also engaged in the development of its ProNeura-Ropinirole product to deliver dopamine agonists for the treatment of Parkinson’s disease. The Company has licensed the rights to commercialize Probuphine in the United States and Canada to Braeburn Pharmaceuticals Sprl (Braeburn).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Titan Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Titan Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.